Docoh
Loading...

UTHR United Therapeutics

News

Pro users get this 30m faster
FDA Declines MannKind - United Therapeutics' Formulated Treprostinil For Lung Disease
18 Oct 21
Biotech, News, Health Care, Small Cap, FDA, Movers, Trading Ideas, General
United Therapeutics Provides An Update On The Progress Of The Tyvaso DPI New Drug Application
18 Oct 21
News, FDA
United Therapeutics Corporation (NASDAQ: UTHR) today announced an update on the U.S.
Shares Of United Therapeutics Quiet; Gizmodo Report 'Drone Delivers Lungs to Transplant Recipient, a Medical First' Mentions Co
13 Oct 21
News
https://gizmodo.com/drone-delivers-lungs-to-transplant-recipient-a-medical-1847854490?utm_source=twitter&utm_medium=SocialMarketing&utm_campaign=dlvrit&utm_content=gizmodo
Attention Biotech Investors: Mark Your Calendar For October PDUFA Dates
1 Oct 21
Biotech, News, Penny Stocks, Health Care, Small Cap, FDA, Top Stories, General
Following a mixed month for regulatory approvals, biotech investors now turn toward a month of plenty as far as Food and Drug Administration decisions are concerned.
United Therapeutics Converts To A Public Benefit Corporation Following Shareholder Approval
30 Sep 21
News
United Therapeutics Corporation (NASDAQ:UTHR) today announced it has officially converted to a public benefit corporation (PBC). The conversion follows shareholder approval of the company's proposal to amend its
United Therapeutics-MannKind's Formulated Tyvaso Shows Benefit In Pulmonary Hypertension Patients
7 Sep 21
Biotech, News, Penny Stocks, Health Care, Small Cap, General
United Therapeutics Corporation (NASDAQ: UTHR) has
88 Biggest Movers From Yesterday
5 Aug 21
News, Penny Stocks, Small Cap, Pre-Market Outlook, Markets, Movers, Trading Ideas
Gainers
58 Stocks Moving In Wednesday's Mid-Day Session
4 Aug 21
News, Penny Stocks, Small Cap, Intraday Update, Markets, Movers, Trading Ideas
Gainers
A Peek Into The Markets: US Stock Futures Mostly lower Ahead Of General Motors Earnings
4 Aug 21
Earnings, News, Eurozone, Futures, Global, Pre-Market Outlook, Markets
Pre-open movers
United Therapeutics Q2 Adj. EPS $4.09 Beats $3.02 Estimate, Sales $446.50M Beat $378.75M Estimate
4 Aug 21
Earnings, News
United Therapeutics (NASDAQ:UTHR) reported quarterly earnings of $4.09 per share which beat the analyst consensus estimate of $3.02 by 35.43 percent. This is a 11.14 percent increase over earnings of $3.68 per share from
Earnings Scheduled For August 4, 2021
4 Aug 21
Earnings, News, Pre-Market Outlook, Markets
Companies Reporting Before The Bell • UroGen Pharma (NASDAQ:URGN) is projected to report earnings for its second quarter.

Press releases

Pro users get this 30m faster
United Therapeutics Provides an Update on the Progress of the Tyvaso DPI™ New Drug Application
18 Oct 21
Press Releases
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Oct. 18, 2021 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ:UTHR) today announced an update on the U.S. Food and Drug Administration (FDA) review of the new
United Therapeutics to Present New Data at CHEST Annual Meeting 2021
11 Oct 21
Press Releases
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Oct. 11, 2021 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ:UTHR), a public benefit corporation with a purpose to provide a brighter future for patients,
United Therapeutics Releases its Annual Corporate Responsibility Report
10 Sep 21
Press Releases
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Sept. 10, 2021 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ:UTHR) today announced the release of its second annual Corporate Responsibility Report with
United Therapeutics Presents Tyvaso DPI™ BREEZE Clinical Data At The European Respiratory Society International Congress 2021
7 Sep 21
Press Releases
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Sept. 7, 2021 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ:UTHR) today presented new clinical data from the BREEZE study evaluating Tyvaso DPI™
United Therapeutics Partners with Former NFL Player Devon Still and His Daughter Leah to Launch "Braving NeuroBLASToma" in Honor of Childhood Cancer Awareness Month
25 Aug 21
Press Releases
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Aug. 25, 2021 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ:UTHR) today announced it is joining forces with former NFL player Devon Still and his daughter
United Therapeutics to Present Tyvaso DPI™ BREEZE Clinical Data at the European Respiratory Society International Congress 2021
24 Aug 21
Press Releases
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Aug. 24, 2021 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ:UTHR) today announced it will present data from a clinical trial studying Tyvaso
Innovators in Pharma Sectors See Potential, Promise in Providing Improved Treatments
5 Aug 21
Small Cap, Opinion, Press Releases
NEW YORK, Aug. 5, 2021 /PRNewswire/ -- A leading cause of death in the United States for men and women of most racial and ethnic groups, heart disease is a pervasive health challenge that destroys lives. The Center for
United Therapeutics Corporation Reports Second Quarter 2021 Financial Results
4 Aug 21
Earnings, Press Releases
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Aug. 4, 2021 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ:UTHR) today announced its financial results for the quarter ended June 30, 2021. Total revenue in
United Therapeutics Corporation To Present At The 2021 Wedbush PacGrow Healthcare Virtual Conference
3 Aug 21
Press Releases
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Aug. 3, 2021 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ:UTHR) announced today that Martine Rothblatt, Ph.D., Chairperson and Chief Executive Officer of
United Therapeutics Corporation To Report Second Quarter 2021 Financial Results Before The Market Opens On Wednesday, August 4, 2021
28 Jul 21
Press Releases
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., July 28, 2021 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ:UTHR) announced today that it will report its second quarter 2021 financial results before the